記住我
Anguita Sánchez M. [Clinical characteristics, treatment and short-term morbidity and mortality of patients with heart failure followed in heart failure clinics. Results of the BADAPIC Registry]. Rev Esp Cardiol 2004; 57: 1159−1169. [In Spanish]
[7] Anguita Sánchez M, Crespo Leiro MG, de Teresa Galván E, et al. Prevalence of heart failure in the Spanish general population aged over 45 years. The PRICE study. Rev Esp Cardiol 2008; 61: 1041−1049. doi: 10.1157/13126044 [8] Martínez Santos P, Bover Freire R, Esteban Fernández A, et al. In-hospital mortality and readmissions for heart failure in Spain. A study of index episodes and 30-day and 1-year cardiac readmissions. Rev Esp Cardiol (Engl Ed) 2019; 72: 998−1004. doi: 10.1016/j.rec.2019.02.004 [9] Christiansen MN, Køber L, Weeke P, et al. Age-specific trends in incidence, mortality, and comorbidities of heart failure in Denmark, 1995 to 2012. Circulation 2017; 135: 1214−1223. doi: 10.1161/CIRCULATIONAHA.116.025941 [10] Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73: 391−398. doi: 10.1038/sj.ki.5002585 [11] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599−3726. doi: 10.1093/eurheartj/ehab368 [12] Esteban-Fernández A, Díez-Villanueva P, Vicent L, et al. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Rev Esp Geriatr Gerontol 2020; 55: 65−69. doi: 10.1016/j.regg.2019.10.002 [13] Osmanska J, Jhund PS. Contemporary management of heart failure in the elderly. Drugs Aging 2019; 36: 137−146. doi: 10.1007/s40266-018-0625-4 [14] Jiménez-Méndez C, Díez-Villanueva P, Bonanad C, et al. Frailty and prognosis of older patients with chronic heart failure. Rev Esp Cardiol (Engl Ed) 2022; 75: 1011−1019. doi: 10.1016/j.recesp.2022.04.019 [15] Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750−1757. doi: 10.1093/eurheartj/ehr254 [16] Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011; 4: 27−35. doi: 10.1161/CIRCHEARTFAILURE.109.932996 [17] [18]2019 Condition-specific measures updates and specifications report hospital-level 30-day risk-standardized mortality measures. (Acute myocardial infarction version 13.0; Chronic obstructive pulmonary disease version 8.0; and Heart failure version 13.0).
[19] Worner F, San Román A, Sánchez PL, et al. The healthcare of patients with acute and critical heart disease. Position of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed) 2016; 69: 239−242. doi: 10.1016/j.recesp.2015.07.018 [20] von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573−577. doi: 10.7326/0003-4819-147-8-200710160-00010 [21] Goldstein H, Spiegelhalter DJ. League tables and their limitations: statistical issues in comparisons of institutional performance. J R Stat Soc 1996; 159: 385−444. doi: 10.2307/2983325 [22] Normand SLT, Glickman ME, Gatsonis CA. Statistical methods for profiling providers of medical care: issues and applications. J Am Stat Assoc 1997; 92: 803−814. doi: 10.1080/01621459.1997.10474036 [23]Pope GC, Ellis RP, Ash AS, et al. Principal inpatient diagnostic cost group model for Medicare risk adjustment. Health Care Financ Rev 2000; 21: 93−118.
[24]Llorens P, Escoda R, Miró Ò, et al. [Characteristics and clinical course of patients with acute heart failure and the therapeutic measures applied in Spanish emergency departments: based on the EAHFE registry (Epidemiology of Acute Heart Failure in Emergency Departments)]. Emergencias 2015; 27: 11−12. [In Spanish].
[25] Sharma K, Mok Y, Kwak L, et al. Predictors of mortality by sex and race in heart failure with preserved ejection fraction: ARIC Community Surveillance Study. J Am Heart Assoc 2020; 9: e014669. doi: 10.1161/JAHA.119.014669 [26] Llorens P, Javaloyes P, Martín-Sánchez FJ, et al. Time trends in characteristics, clinical course, and outcomes of 13, 791 patients with acute heart failure. Clin Res Cardiol 2018; 107: 897−913. doi: 10.1007/s00392-018-1261-z [27] Martínez-Sellés M, García Robles JA, Prieto L, et al. Systolic dysfunction is a predictor of long term mortality in men but not in women with heart failure. Eur Heart J 2003; 24: 2046−2053. doi: 10.1016/j.ehj.2003.07.007 [28] [29] De Maria R, Gori M, Marini M, et al. Temporal trends in characteristics, treatment, and outcomes of heart failure in octogenarians over two decades. Rev Esp Cardiol (Engl Ed) 2022: S1885−5857(22)00061-5. doi: 10.1016/j.rec.2022.03.002 [30] Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993; 342: 1032−1036. doi: 10.1016/0140-6736(93)92884-V [31] Marttini Abarca J, Fernández Arana L, Martín-Sánchez FJ, et al. In-hospital mortality risk score for very old patients hospitalized with decompensated chronic heart failure. Eur Geriatr Med 2018; 9: 61−69. doi: 10.1007/s41999-017-0008-0 [32] Vidán MT, Blaya-Novakova V, Sánchez E, et al. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. Eur J Heart Fail 2016; 18: 869−875. doi: 10.1002/ejhf.518 [33] Chivite D, Formiga F, Corbella X, et al. Basal functional status predicts one-year mortality after a heart failure hospitalization in elderly patients: the RICA prospective study. Int J Cardiol 2018; 254: 182−188. doi: 10.1016/j.ijcard.2017.10.104 [34] Bonilla-Palomas JL, Anguita-Sánchez MP, Elola-Somoza FJ, et al. Thirteen-year trends in hospitalization and outcomes of patients with heart failure in Spain. Eur J Clin Invest 2021; 51: e13606. doi: 10.1111/eci.13606 [35] Sánchez-Salado JC, Burgos V, Ariza-Solé A, et al. Trends in cardiogenic shock management and prognostic impact of type of treating center. Rev Esp Cardiol (Engl Ed) 2020; 73: 546−553. doi: 10.1016/j.recesp.2019.10.009 [36] Gómez-Otero I, Ferrero-Gregori A, Varela Román A, et al. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure. Rev Esp Cardiol (Engl Ed) 2017; 70: 338−346. doi: 10.1016/j.recesp.2016.08.019 [37] Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768−777. doi: 10.1016/j.jacc.2007.04.064 [38] Grigorian-Shamagian L, Otero Raviña F, Abu Assi E, et al. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of > 600 deaths in a community long-term study. Am Heart J 2008; 156: 1184−1190. doi: 10.1016/j.ahj.2008.07.011 [39] Bernal JL, Barrabés JA, Íñiguez A, et al. Clinical and administrative data on the research of acute coronary syndrome in Spain. Minimum Basic Data Set validity. Rev Esp Cardiol (Engl Ed) 2019; 72: 56−62. doi: 10.1016/j.rec.2018.01.026 [40] Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with an acute myocardial infarction. Circulation 2006; 113: 1683−1692. doi: 10.1161/CIRCULATIONAHA.105.611186 [41] Krumholz HM, Merrill AR, Schone EM, et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes 2009; 2: 407−413. doi: 10.1161/CIRCOUTCOMES.109.883256
留言 (0)